Loading...
Docoh

Impel Pharmaceuticals (IMPL)

Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Company profile

Ticker
IMPL
Exchange
Website
CEO
Michael Hite
Employees
Incorporated
Location
Fiscal year end
Former names
IMPEL NEUROPHARMA INC
SEC CIK
Subsidiaries
Impel NeuroPharma Australia PTY LTD ...
IRS number
263058238

IMPL stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 22
12 Aug 22
26 Apr 23
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 129.84M 129.84M 129.84M 129.84M 129.84M 129.84M
Cash burn (monthly) (no burn) (no burn) 8.99M 7.68M 8.07M 6.72M
Cash used (since last report) n/a n/a 39.74M 33.97M 35.67M 29.71M
Cash remaining n/a n/a 90.1M 95.87M 94.16M 100.12M
Runway (months of cash) n/a n/a 10.0 12.5 11.7 14.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
16 Jun 22 David D. Allison Stock Option Common Stock Grant Acquire A No No 8.65 12,789 110.62K 12,789
16 Jun 22 Parker H Stewart Stock Option Common Stock Grant Acquire A No No 8.65 12,789 110.62K 12,789
16 Jun 22 Timothy S Nelson Stock Option Common Stock Grant Acquire A No No 8.65 12,789 110.62K 12,789
16 Jun 22 Mahendra Shah Stock Option Common Stock Grant Acquire A No No 8.65 12,789 110.62K 12,789
16 Jun 22 Wilfong Diane E. Stock Option Common Stock Grant Acquire A No No 8.65 12,789 110.62K 12,789
13F holders Current Prev Q Change
Total holders 46 49 -6.1%
Opened positions 5 14 -64.3%
Closed positions 8 13 -38.5%
Increased positions 13 17 -23.5%
Reduced positions 12 4 +200.0%
13F shares Current Prev Q Change
Total value 272.63M 308.74M -11.7%
Total shares 26.78M 27.03M -0.9%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Kohlberg Kravis Roberts & Co. 4.14M $26.35M 0.0%
KKR Iris Investors 3.8M $57.23M 0.0%
5AM Venture Management 2.88M $18.38M 0.0%
Vivo Capital VIII 2.88M $43.42M 0.0%
Vivo Capital 2.88M $18.38M 0.0%
venBio Global Strategic Fund II 2.76M $41.54M 0.0%
venBio Partners 2.76M $17.58M 0.0%
5AM Ventures V 2.31M $34.76M 0.0%
Vanguard 531.78K $3.39M +8.1%
DCF Advisers 367.06K $2.34M +43.4%
Largest transactions Shares Bought/sold Change
Point72 Asset Management 0 -208.76K EXIT
Two Sigma Investments 0 -142.1K EXIT
DCF Advisers 367.06K +111.03K +43.4%
Two Sigma Advisers 0 -58.4K EXIT
Vanguard 531.78K +40.03K +8.1%
Renaissance Technologies 33.2K +33.2K NEW
Geode Capital Management 161.79K +32.99K +25.6%
Anson Funds Management 0 -17.73K EXIT
Millennium Management 0 -14.83K EXIT
UBS UBS Group AG - Registered Shares 1.96K -13.71K -87.5%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Academy, Africa, aimed, arrangement, assumption, bifurcated, bifurcation, Brazil, Britain, Canada, captioned, car, Carlo, Chairman, compound, embedded, estate, expedient, exploring, fixed, fleet, floor, fourth, France, geopolitical, Germany, Great, half, highlighted, hoc, Hong, host, implicit, impute, imputed, inaugural, India, instability, intercreditor, intermittent, Israel, Japan, Kong, Korea, Mexico, mild, military, monetization, Monte, multiplied, Neurology, Oaktree, occupy, Overnight, pain, peer, penetrate, perfected, playing, ranking, real, recipient, reclassification, refill, repay, repeat, repurchase, rescinding, residual, RIF, role, ROU, royalty, RSU, Russia, salesforce, shareholder, simulation, SOFR, solution, South, suggest, Switzerland, thereon, thereto, therewith, threshold, tier, tiered, TSR, Ukraine, undiscounted, unpaid, unrestricted, upfront, vehicle, weighted, Zealand
Removed: acceleration, acceptability, adding, adhering, allocated, anesthesiologist, appointed, apportioned, assumed, ASU, biologic, Bipartisan, brand, cancelled, cavity, Center, certified, classifying, committed, concur, corrective, determinable, dual, effected, enrolled, estimating, exchanged, expanded, FASB, faster, feasible, framework, Freestanding, freeze, fullest, implanted, impurity, inaccurately, indemnification, indemnified, inform, infused, injected, Innovation, innovative, instilled, Institute, intention, issuable, ix, led, lessee, leverage, licensure, liquidity, locality, lost, maximum, memorandum, methodology, mitigate, nondeductible, nonqualified, noted, opening, optional, Originally, outpatient, oversee, par, persist, pool, postpone, poverty, preceding, prematurely, presence, preventive, prime, principle, proportionately, proscribed, ramp, ratably, rating, reached, recognizing, reconsider, remained, remediated, removing, reposition, resumption, retroactively, risky, ruling, safest, scenario, seasonal, separation, SPAC, speculative, split, subjected, Subtopic, successor, suffered, underwritten, unnecessarily, vi, vii, viii, withdrawn, worked

Patents

Utility
Respiratory Tract Delivery of Levodopa and Dopa Decarboxylase Inhibitor for Treatment of Parkinson's Disease
28 Jul 22
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
Utility
Intranasal device with inlet interface
26 Jul 22
A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip that removably couples to the actuator body.
Utility
Nasal Drug Delivery Device
24 Mar 22
A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound.
Utility
Intranasal delivery of olanzapine by precision olfactory device
22 Mar 22
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours.
Utility
In-line nasal delivery device
8 Mar 22
A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.